WASHINGTON – Eighteen Americans spent weeks in a specialized treatment unit at Nebraska Medicine in Omaha, completing a 42-day medical monitoring protocol, the full incubation window for Andes virus, the only form of hantavirus known to pass from person to person. They had no symptoms. None developed the disease. On June 21, the Centers for Disease Control and Prevention confirmed that every one of the 18 had cleared the monitoring window without incident.
The announcement marked the end of the American chapter of an outbreak that, for nearly three months, had placed health authorities across 32 countries on alert and forced contact tracers to track more than 600 people on five continents. On June 24, the CDC formally wound down its response to the MV Hondius outbreak. The following day, the World Health Organization issued its Disease Outbreak Notice 604, rating the risk of continued spread as “very low” and confirming that no secondary community transmission had been documented anywhere in the world.
The MV Hondius, a polar expedition vessel operated by Dutch company Oceanwide Expeditions, had departed Ushuaia, Argentina, on April 1 with 114 passengers and 61 crew members representing 23 nationalities. The itinerary took the ship through Antarctica and the South Atlantic over six weeks. By the time the vessel docked and passengers dispersed to their home countries, 13 people had contracted Andes virus. Three died, a case fatality rate of roughly 23 percent, consistent with historical records of hantavirus pulmonary syndrome and significantly higher than most respiratory diseases.
The source of the exposure remains unconfirmed. Andes virus is endemic to Argentina, Chile, and neighboring parts of South America, carried by long-tailed pygmy rice rats and related rodents. Investigators have not publicly identified where or how passengers encountered an infected animal: whether in port facilities in Ushuaia before departure, during shore excursions, or somewhere aboard the ship itself. That question may never receive a definitive answer.
What public health officials could trace with greater precision was what happened after. The CDC coordinated with counterparts in 31 other countries and nine European Union member states, extending the hantavirus alert that spanned 32 countries and 23 nationalities from the outbreak’s earliest weeks into a sustained monitoring operation. Every passenger and crew member assessed at elevated risk underwent the full 42-day observation, a period chosen because Andes hantavirus carries one of the longer known incubation windows of any hemorrhagic-type pathogen.
The 18 Americans placed into monitoring were housed at the Nebraska Medicine Regional Emerging Special Pathogen Treatment Center in Omaha, a facility designed to contain pathogens requiring strict biocontainment protocols, among them the Bundibugyo Ebola strain currently circulating in the Democratic Republic of Congo. No new cases emerged from the American monitoring cohort. CDC officials said in their June 24 statement that the outcome validated the contact tracing methodology applied across all 32 countries.
In Europe, nine EU and EEA member states conducted parallel monitoring of their returning nationals and crew members. By the date of the WHO notice, all had cleared. The aggregate result across 32 countries: zero community transmission events, zero secondary infections outside of the original exposure window aboard the MV Hondius.
The zero-spread result is less surprising than it might appear. Andes virus does not transmit the way influenza or SARS-CoV-2 do. It spreads between humans only under conditions of very close, prolonged contact, typically household members or healthcare workers without adequate protective equipment. The absence of community spread tracks with how the pathogen behaves under standard isolation precautions, not a dramatic reversal of its biology. What made containment achievable here was logistics, not luck.
A polar expedition vessel dispersing passengers from 23 countries to five continents within days of docking created the kind of international contact tracing challenge that health agencies prepare for and rarely face at this scale in practice. That the system held, with no community infections surfacing in any of the 32 monitoring countries, represents a demonstration under real conditions of what rapid international notification and sustained coordination across 32 health ministries can accomplish. Whether that infrastructure scales to a more transmissible pathogen remains one of the central unanswered questions in global health preparedness.
It accomplished that at a cost of three lives. The three passengers who died, whose nationalities have not been publicly disclosed by Oceanwide Expeditions or Dutch health authorities, received supportive care for hantavirus pulmonary syndrome: supplemental oxygen, mechanical ventilation when respiratory failure progressed, and no approved antiviral. Ribavirin, sometimes used in related hantavirus cases, remains investigational for Andes-specific infections. No vaccine exists for any Andes hantavirus strain.
Whether the ten survivors will face lasting consequences is a question neither the WHO notice nor the CDC statement addresses. Survivors of hantavirus pulmonary syndrome frequently report reduced lung capacity, persistent fatigue, and impaired exercise tolerance for months or years after acute illness. The longitudinal data specific to Andes virus infection is thin. For the passengers who boarded the MV Hondius in Argentina and came home to a biocontainment unit, the formal end of monitoring is not the same thing as a clean bill of health. The ship remains at port. Its next expedition has not been scheduled.
